LT6202B - Composition for nutritional or pharmaceutical biopreparation - Google Patents
Composition for nutritional or pharmaceutical biopreparation Download PDFInfo
- Publication number
- LT6202B LT6202B LT2013502A LT2013502A LT6202B LT 6202 B LT6202 B LT 6202B LT 2013502 A LT2013502 A LT 2013502A LT 2013502 A LT2013502 A LT 2013502A LT 6202 B LT6202 B LT 6202B
- Authority
- LT
- Lithuania
- Prior art keywords
- composition
- lactobacillus
- lactobacteria
- bifidobacteria
- bifidobacterium
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 42
- 235000016709 nutrition Nutrition 0.000 title description 3
- 241000186000 Bifidobacterium Species 0.000 claims abstract description 19
- 239000006041 probiotic Substances 0.000 claims abstract description 18
- 235000018291 probiotics Nutrition 0.000 claims abstract description 18
- 239000002028 Biomass Substances 0.000 claims abstract description 11
- 241001608472 Bifidobacterium longum Species 0.000 claims abstract description 7
- 241000218588 Lactobacillus rhamnosus Species 0.000 claims abstract description 7
- 229940009291 bifidobacterium longum Drugs 0.000 claims abstract description 7
- 239000000463 material Substances 0.000 claims abstract description 7
- 241000186015 Bifidobacterium longum subsp. infantis Species 0.000 claims abstract description 6
- 229940004120 bifidobacterium infantis Drugs 0.000 claims abstract description 6
- 241000186016 Bifidobacterium bifidum Species 0.000 claims abstract description 5
- 235000013958 Lactobacillus casei Nutrition 0.000 claims abstract description 5
- 241000186840 Lactobacillus fermentum Species 0.000 claims abstract description 5
- 241000186604 Lactobacillus reuteri Species 0.000 claims abstract description 5
- 229940002008 bifidobacterium bifidum Drugs 0.000 claims abstract description 5
- 230000004071 biological effect Effects 0.000 claims abstract description 5
- 230000001332 colony forming effect Effects 0.000 claims abstract description 5
- 229940017800 lactobacillus casei Drugs 0.000 claims abstract description 5
- 229940012969 lactobacillus fermentum Drugs 0.000 claims abstract description 5
- 229940001882 lactobacillus reuteri Drugs 0.000 claims abstract description 5
- 238000011282 treatment Methods 0.000 claims abstract description 5
- 235000015872 dietary supplement Nutrition 0.000 claims abstract description 4
- 238000011321 prophylaxis Methods 0.000 claims abstract description 3
- 241000186012 Bifidobacterium breve Species 0.000 claims abstract 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 18
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 18
- 239000005913 Maltodextrin Substances 0.000 claims description 9
- 229920002774 Maltodextrin Polymers 0.000 claims description 9
- 235000019359 magnesium stearate Nutrition 0.000 claims description 9
- 229940035034 maltodextrin Drugs 0.000 claims description 9
- 239000000377 silicon dioxide Substances 0.000 claims description 9
- 230000000529 probiotic effect Effects 0.000 claims description 8
- 239000002775 capsule Substances 0.000 claims description 7
- 241000186660 Lactobacillus Species 0.000 claims description 4
- 239000002552 dosage form Substances 0.000 claims description 4
- 208000036649 Dysbacteriosis Diseases 0.000 claims description 3
- 208000027244 Dysbiosis Diseases 0.000 claims description 3
- 239000002671 adjuvant Substances 0.000 claims description 3
- 230000007140 dysbiosis Effects 0.000 claims description 3
- 208000015181 infectious disease Diseases 0.000 claims description 3
- 241000736262 Microbiota Species 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 230000007613 environmental effect Effects 0.000 claims description 2
- 230000002496 gastric effect Effects 0.000 claims description 2
- 230000002458 infectious effect Effects 0.000 claims description 2
- 230000004054 inflammatory process Effects 0.000 claims description 2
- 239000008188 pellet Substances 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 229940039696 lactobacillus Drugs 0.000 claims 2
- 230000001629 suppression Effects 0.000 claims 1
- 240000001046 Lactobacillus acidophilus Species 0.000 abstract description 6
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 abstract description 6
- 229940039695 lactobacillus acidophilus Drugs 0.000 abstract description 6
- 229940072205 lactobacillus plantarum Drugs 0.000 abstract description 6
- 240000006024 Lactobacillus plantarum Species 0.000 abstract description 5
- 235000013965 Lactobacillus plantarum Nutrition 0.000 abstract description 5
- 238000002360 preparation method Methods 0.000 abstract description 5
- 230000000694 effects Effects 0.000 abstract description 4
- 244000199866 Lactobacillus casei Species 0.000 abstract description 3
- 239000000047 product Substances 0.000 description 7
- 230000004060 metabolic process Effects 0.000 description 5
- 241000186018 Bifidobacterium adolescentis Species 0.000 description 4
- 238000001228 spectrum Methods 0.000 description 4
- 230000035899 viability Effects 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000007903 gelatin capsule Substances 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 235000020299 breve Nutrition 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- ZFRKQXVRDFCRJG-UHFFFAOYSA-N skatole Chemical compound C1=CC=C2C(C)=CNC2=C1 ZFRKQXVRDFCRJG-UHFFFAOYSA-N 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 230000000153 supplemental effect Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000589989 Helicobacter Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010022678 Intestinal infections Diseases 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 208000019802 Sexually transmitted disease Diseases 0.000 description 1
- 206010046914 Vaginal infection Diseases 0.000 description 1
- 201000008100 Vaginitis Diseases 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 235000015140 cultured milk Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 235000021001 fermented dairy product Nutrition 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000035987 intoxication Effects 0.000 description 1
- 231100000566 intoxication Toxicity 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005706 microflora Species 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 208000007442 rickets Diseases 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229940074386 skatole Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
Išradimas priklauso biotechnologijos sričiai, būtent, probiotikų preparatams ir gali būti naudojamas kaip maisto papildas arba gydomasis profilaktinis preparatas.The present invention relates to the field of biotechnology, namely to probiotic preparations and may be used as a dietary supplement or as a therapeutic prophylactic preparation.
Yra žinomas konsorciumas iš 5-kių bifido bakterijų, parinktų iš grupės štamų Bifidobacterium bifidum, Bifidobacterium longum, Bifidobacterium adolescentis, Bifidobacterium infantis, Bididobacterium breve, kuris naudojamas rauginto pieno nefermentuotiems produktams gaminti, biologiškai aktyviems priedams gaminti (žiūrėti Rusijos patentą Nr. 2 261 909).There is a known consortium of 5 bifid bacteria selected from the group of strains Bifidobacterium bifidum, Bifidobacterium longum, Bifidobacterium adolescentis, Bifidobacterium infantis, Bididobacterium breve, which is used to make fermented milk non-fermented products 9 (see Patent Nos. 9). ).
Šio konsorciumo trūkumas yra siauras pritaikymas, nes tinka naudoti tik rauginto pieno produktų gamyboje ir neišlaiko stabilumo ir gyvybingumo skystose terpėse. Veikiant virškinamojo trakto agresyvios terpės faktoriams praranda gyvybingumą ir efektyvumą.The disadvantage of this consortium is its narrow application because it is only suitable for use in the manufacture of fermented dairy products and does not maintain stability and viability in liquid media. Aggressive media loses vitality and efficiency when exposed to gastrointestinal tract agents.
Yra žinomas biopreparatas bifidobakterijų ir laktobakterijų pagrindu, skirtas disbakteriozei bei infekcinių skrandžio ir žarnyno trakto susirgimų profilaktikai ir gydymui, turintis sausos biomasės konsorciumą iš bifidobakterijų, apimančių štamo Bifidobacterium adolescentis B-1 nuo 108 iki 101° KSV ir Lactobacillus acidophilus AT41 nuo 10® iki 101° KSV viename grame sausos biomasės ir papildomas medžiagas, skirtas vaistų formai sudaryti, kur sausos konsorciumo biomasės komponentai masės % sudaro: bifidobakterijos ir laktobakterijos 0,5 - 10,0, o likusią dalį papildomos medžiagos (žiūrėti Rusijos išradimo paraišką Nr.2003 136785).It is known Bifidobacteria and lactobacilli biopreparation basis for dysbacteriosis and infectious gastrointestinal tract disorders for the treatment of dry biomass containing a consortium of bifidobacteria comprising Bifidobacterium adolescentis strain B-1 10 8 to 10 1 ° CFU Lactobacillus acidophilus AT41 from 10® to 10 1 CFU per gram of dry biomass and auxiliary materials for formulation, wherein the biomass components of the dry consortium consist of: bifidobacteria and lactobacteria 0.5 to 10.0% and the remainder of the auxiliary material (see Russian patent application no. 2003 136785).
Artimiausias pagal sudėtį yra biopreparatas apimantis probiotikus iš bifidobakterijų ir laktobakterijų bei papildomas medžiagas, probiotikų bifidobakterijos yra parinktos iš štamų grupės, susidedančios iš Bifidobacterium infantis, Bifidobacterium longum, Bifidobacterium bifidum 1, Bifidobacterium adolescentis, Bifidobacterium breve, laktobakterijos yra parinktos iš štamų grupės, susidedančios iš Lactobacillus acidophilus, Lactobacillus plantarum, o pasirinktinai papildomos medžiagos apima probiotikų gyvybingumą skatinanti medžiaga, antioksidantas bei užpildas, kurioje probiotikų bendras biologinis aktyvumas viename grame sausos biomasės yra nuo maždaug 5 χ 109 iki maždaug 8 χ 1010 KSV (kolonijas sudarančių vienetų), bei sudaro nuo maždaug 25 iki maždaug 30 kompozicijos masės %, o likusią dalį sudaro papildomos medžiagos (žiūrėti išradimo aprašymą pagal Lietuvos patentą Nr.5578, 2007 08 20)The closest by composition is a biopreparation comprising probiotics from bifidobacteria and lactobacteria and adjuvants, probiotic bifidobacteria are selected from the group consisting of strains consisting of Bifidobacterium infantis, Bifidobacterium longum, Bifidobacterium bifidum 1, Bifidobacterium adolescentis, Bifidobacterium adolescentis, Lactobacillus acidophilus, Lactobacillus plantarum, and optionally, the additional substances include a probiotic viability enhancer, an antioxidant, and a filler having a total biological activity of probiotics from about 5 x 10 9 to about 8 x 10 10 CFU (colony forming units), and from about 25 to about 30% by weight of the composition, the remainder being supplemental materials (see description of the invention according to Lithuanian Patent No. 5578, August 20, 2007)
Šio biopreparato trūkumas yra siauras veikimo spektras dalyvaujant medžiagų apykaitos procesuose, nes apima nedidelį kiekį laktobakterijų štamų, papildančių vienas kitą savo naudingomis savybėmis.The disadvantage of this biopreparation is the narrow spectrum of action involved in metabolic processes because of the small amount of lactobacterial strains that complement each other with their beneficial properties.
Išradimu siekiama sukurti biopreparatą, kuris turėtų platesnį veikimo spektrą dalyvaujant medžiagų apykaitos procesuose, geriau išlaikytų bakterijų stabilumą ir gyvybingumą.The purpose of the invention is to provide a biopreparation which has a broader spectrum of activity in the metabolic process, better maintaining bacterial stability and viability.
Išradimo esmė yra ta, kad maistinio arba farmacinio biopreparato kompozicijoje, apimančioje probiotikus iš bifidobakterijų ir laktobakterijų bei papildomas medžiagas, kurioje probiotikų bifidobakterijos yra parinktos iš štamų, tokių kaip Bifidobacterium infantis, Bifidobacterium longum, Bifidobacterium bifidum Bifidobacterium breve, laktobakterijos yra parinktos iš štamų, tokių kaip Lactobacillus acidophilus, Lactobacillus plantarum, kompozicija papildomai turi laktobakterijas parinktas iš štamų Lactobacillus fermentum, Lactobacillus reuteri, Lactobacillus casei ir Lactobacillus rhamnosus, kurioje probiotikų iš bifidobakterijų ir laktobakterijų bendras biologinis aktyvumas viename grame biomasės yra nuo maždaug 1,5 χ 1010 iki maždaug 1,5 χ 1011 KSV (kolonijas sudarančių vienetų) bei sudaro nuo maždaug 40 iki maždaug 42 kompozicijos masės %, o likusią dalį sudaro pasirinktos papildomos medžiagos.It is an object of the present invention that a composition of a nutritional or pharmaceutical biopreparation comprising probiotics from bifidobacteria and lactobacteria and adjuvants wherein the probiotic bifidobacteria are selected from strains such as Bifidobacterium longum, Bifidobacterium lifidum, as Lactobacillus acidophilus, Lactobacillus plantarum, the composition further comprises lactobacteria strains selected from Lactobacillus fermentum, Lactobacillus reuteri, Lactobacillus casei and Lactobacillus rhamnosus in which the probiotic lactobacilli and bifidobacteria in the total biological activity per gram of biomass is about 1.5 χ 10 10 to about 1 , 5 χ 10 11 CFUs (colony forming units), and from about 40 to about 42% by weight of the composition, with the remainder being selected from additional ingredients.
Pasirinktos papildomos medžiagos kompozicijoje apima maltodekstriną, magnio stearatą ir silicio dioksidą, kur maltodekstrinas sudaro maždaug 35,19 kompozicijos masės %, magnio stearatas sudaro 1,17 kompozicijos masės %, ir silicio dioksidas sudaro maždaug 0,29 kompozicijos masės % .Selected additional ingredients in the composition include maltodextrin, magnesium stearate and silica, wherein maltodextrin represents about 35.19% by weight of the composition, magnesium stearate represents 1.17% by weight of the composition, and silica comprises about 0.29% by weight of the composition.
Kompozicija yra per burną vartojamos vienetinės dozės formos, kuri gali būti suformuota kaip kapsulė, arba kaip tabletė, arba kaip žirnelis, arba miltelių pavidalo ir gali būti panaudota kaip maisto papildas arba vaistas virškinamojo trakto disbakteriozių profilaktikai arba gydymui, infekciniams ir uždegiminiams procesams slopinti bei atstatyti dinamišką organizmo mikrobiotos ir aplinkos pusiausvyros būklę.The composition is in a unit dosage form for oral administration, which may be in the form of a capsule, tablet, pellet, or powder and may be used as a dietary supplement or as a medicine for the prophylaxis or treatment of gastrointestinal dysbacteriosis, dynamic equilibrium between the microbiota of the body and the environment.
Pasiūlyta kompozicija dėl bifidobakterijų ir laktobakterijų įvairovės ir tarpusavio suderinamumo turi žymiai platesnį veikimo spektrą dalyvaujant medžiagų apykaitos procesuose bei didesnį stabilumą.The proposed composition, due to the diversity and compatibility of bifidobacteria and lactobacteria, has a much broader spectrum of activity involved in metabolic processes and greater stability.
Pasiūlyta maistinio arba farmacinio biopreparato kompozicija apima probiotikus iš bifidobakterijų ir laktobakterijų, kurie yra parinkti iš štamųThe proposed composition of a nutritional or pharmaceutical biopreparation comprises probiotics from bifidobacteria and lactobacteria selected from strains
Bifidobacterium bifidum, ATCC 29521;Bifidobacterium bifidum, ATCC 29521;
Lactobacillus acidophilus, ATCC 4356;Lactobacillus acidophilus, ATCC 4356;
Bifidobacterium brevis, produkto kodas: LactoStab, SGB01;Bifidobacterium brevis, product code: LactoStab, SGB01;
Bifidobacterium infantis, produkto kodas: LactoStab, SGB03;Bifidobacterium infantis, product code: LactoStab, SGB03;
Lactobacillus fermentum, produkto kodas: LactoStab, SGL10;Lactobacillus fermentum, product code: LactoStab, SGL10;
Lactobacillus reuteri, produkto kodas: LactoStab, SGL01;Lactobacillus reuteri, product code: LactoStab, SGL01;
„Nutraceutica“ s.r.l. Via Idice 27/01,40050 Monterenzio, IT;Nutraceutica s.r.l. Via Idice 27 / 01,40050 Monterenzio, IT;
Bifidobacterium longum, produkto kodas 68936, 01-05-2010;Bifidobacterium longum, product code 68936, 01-05-2010;
FERM 100351 FT CHR Hansen;FERM 100351 FT CHR Hansen;
Chr. Hansen A/S, Boge Alle 10-12—2970 Horsholm, DKChr. Hansen A / S, Boge Alle 10-12-2970 Horsholm, DK
Lactobacillus plantarum, prod. specifikacija “DuoLac-Lactobacillus plantarum LP1“, 2008/12/15; FERM 300 500FT, „CELL BIOTECH EUROPE A/S“Havnegade 39, 1058 Kopenhaga, DKLactobacillus plantarum, prod. specification DuoLac-Lactobacillus plantarum LP1, 12/15/2008; FERM 300 500FT, CELL BIOTECH EUROPE A / S Havnegade 39, 1058 Copenhagen, DK
Lactobacillus rhamnosus, produkto kodas THT 030901, E-09-10/044 (16S/ITS),Lactobacillus rhamnosus, product code THT 030901, E-09-10 / 044 (16S / ITS),
FERM600200 FT THT;FERM600200 FT THT;
„THT s.a.. Chee dEghezee, 36-5081 La Bruyere, BETHT s.a .. Chee dEghezee, 36-5081 La Bruyere, BE
Lactobacillus caseiLactobacillus casei
Probiotikų padermės parinktos remiantis mokslininkų ir biotechnologų tyrimais, pateikiamomis padermių charakteristikomis, jų ypatinga reikšme organizme vykstančiuose medžiagų apykaitos procesuose. Probiotikų padermių skirtingas antagonistinis,fermentinis, imunogeninis aktyvumas sudaro jų komplekso platesnį veikimo spektrą - neleidžia prisitvirtinti ir daugintis infekcijas ir uždegiminius procesus sukeliančioms bakterijoms, gamina medžiagas (bakteriocinus, rūgštis ir kt) naikinančias grybelius, patogenines ir sąlyginai patogenines bakterijas, sintetina fermentus, skaidančius organizmo nesuvirškintas maisto medžiagas, slopina alergines reakcijas, mažina riziką susirgti atopiniu dermatitu, dalyvauja B ir K grupės vitaminų sintezėje, padeda įsisavinti Ca, Mg, Zn, Fe, mažina riziką susirgti rachitu ir osteoporoze, stimuliuoja opų gijimą, naikina opas sukeliančias bakterijas Helicobacter pylori, mažina cholesterolio kiekį, įtakoja tulžies rūgščių apykaitą, saugo nuo aterosklerozės, padeda kompleksiškai gydyti žarnyno ir šlapimo takų infekcijas,vaginitus ir vaginozes, suskaido patekusias iš aplinkos ir endogeninės kilmės nuodingas medžiagas, mažina intoksikaciją, slopina vėžinių ląstelių augimą, auglių susidarymą, neutralizuoja kancerogenines nitritų ir nitratų savybes, mažina riziką susirgti virusinėmis ligomis, tame tarpe ir lytiškai plintančiomis, aktyvina imunitetą, stimuliuoja antikūnų ypač IgA, fagocitų, limfocitų, iterferono, lizocimo sintezę, mažina storosios žarnos pH ir taip slopina patogeninių, puvimo ir rūgimo bakterijų augimą, lemia nuolatinę dujų sudėtį ir kvapą, mažina indolo, skatolo, H2S susidarymą, padeda esant įvairios kilmės viduriavimui, vidurių užkietėjimui, normalizuoja išmatų konsistenciją ir tuštinimąsj, skaido angliavandenius, mažina cukraus kiekį kraujuje, lanolio rūgštį paverčia labai reikalinga lanolino rūgštimi, šalina laisvuosius radikalus, slopina lipidų oksidaciją kepenyse.Probiotic strains have been selected based on the research of scientists and biotechnologists on the characteristics of the strains and their particular importance in the metabolic processes in the body. The different antagonistic, enzymatic, immunogenic activity of the probiotic strains forms a broader spectrum of their activity - prevents the attachment and multiplication of bacteria causing infections and inflammatory processes, produces fungi, pathogenic and conditionally pathogenic bacteria, synthesizing enzymes, undigested nutrients, suppresses allergic reactions, reduces risk of atopic dermatitis, participates in synthesis of B and K vitamins, assimilates Ca, Mg, Zn, Fe, reduces risk of rickets and osteoporosis, stimulates ulcer healing, kills ulcerative bacteria Helicobacter p lowers cholesterol, influences bile acid metabolism, protects against atherosclerosis, helps in complex treatment of intestinal and urinary tract infections, vaginitis and vaginosis, decomposes toxic substances of environmental and endogenous origin, reduces intoxication, inhibits cancer cell growth, tumor formation, neutralizes carcinogenic properties of nitrite and nitrate, reduces risk of viral diseases, including sexually transmitted diseases, activates immunity, stimulates the synthesis of antibodies especially IgA, phagocytes, lymphocytes, iterferon, lysozyme, pH also inhibits the growth of pathogenic, decaying and fermenting bacteria, determines the constant gas composition and odor, reduces indole, skatole, H2S formation, assists with various origins of diarrhea, constipation, normalizes stool consistency and emptying, decomposes carbohydrates, lowers blood sugar, Converts lanolic acid into the much needed lanolin acid, removes free radicals, inhibits lipid oxidation in the liver.
Visų paminėtų štamų gavimas yra analogiškas, būtent, kiekvienas jų išauginamas skystoje mitybinėje terpėje, atliekant tris pasėlius. Išauginta kultūra yra koncentruojama ultrafiltraciniu metodu, j gautą biomasę pridedama 6-10 masės % sacharozės ir 0,5-2 masės % želatinos ir išdžiovinama liofilizacijos metodu. 100 g sausos biomasės yra 5-20 g želatinos, 60-70 g sacharozės, 7-8 g biokultūros ląstelių ir 9-10 g terpės druskų. Atliekama bifidobakterijų ir laktobakterijų gyvybingumo kontrolė, švarumo kontrolė, kad nebūtų pašalinės mikrofloros, ir nustatoma liekamoji drėgmė.All of the above strains are obtained in an analogous manner, namely, each is grown in a liquid medium with three crops. The cultured culture is concentrated by ultrafiltration, 6-10% by weight of sucrose and 0.5-2% by weight of gelatin are added to the resulting biomass and lyophilized. 100 g of dry biomass contains 5-20 g of gelatin, 60-70 g of sucrose, 7-8 g of bioculture cells and 9-10 g of medium salts. Bifidobacteria and lactobacteria are monitored for viability, purity for foreign microflora, and residual moisture.
Prisilaikant techninės dokumentacijos normatyvų, gautos sausos mikrobinės masės susmulkinamos ir sumaišomos pasirinktinai su papildomomis medžiagomis, tokiomis kaip maltodekstrinas, magnio stearatas, silicio dioksidas.The resulting dry microbial masses are pulverized and optionally mixed with excipients such as maltodextrin, magnesium stearate, silica in accordance with the specifications of the technical documentation.
Bendras biologinis aktyvumas viename grame gautos biomasės turi būti nuo nuo maždaug 1,5 χ 1010 iki maždaug 1,5 χ 1011 KSV (kolonijas sudarančių vienetų) bei sudaro nuo maždaug 40 iki maždaug 42 kompozicijos masės %, o likusią dalį sudaro pasirinktos papildomos medžiagos. Pasirinktos papildomos medžiagos kompozicijoje apima maltodekstriną, magnio stearatą ir silicio dioksidą, kur maltodekstrinas sudaro maždaug 35,19 kompozicijos masės %, magnio stearatas sudaro maždaug 1,17 kompozicijos masės %, silicio dioksidas sudaro maždaug 0,29 kompozicijos masės %.The total biological activity per gram of biomass obtained shall be from about 1.5 χ 10 10 to about 1.5 χ 10 11 CFU (colony forming units) and shall be from about 40 to about 42% by weight of the composition, with the remainder being selected from additional additives. materials. Selected additional ingredients in the composition include maltodextrin, magnesium stearate and silica, wherein maltodextrin represents about 35.19% by weight of the composition, magnesium stearate represents about 1.17% by weight of the composition, and silica comprises about 0.29% by weight of the composition.
Kai kompozicijos vienetinė dozė yra suformuota kaip kapsulė, tuomet želatininė kapsulė sudaro maždaug 2,2 kompozicijos masės %.When a unit dosage form of the composition is formulated as a capsule, the gelatin capsule will then comprise approximately 2.2% by weight of the composition.
Pavyzdys.An example.
Kompozicijos vienetinę per burną vartojamą kapsulės pavidalo dozę sudaro 341 mg sausos biomasės, kurios sudėtis pateikta lentelėje:The unit dosage form of the composition for oral administration in capsule form is 341 mg of dry biomass, the composition of which is as follows:
Pavyzdyje pateiktos kapsulės sausos biomasės bendras biologinis aktyvumas yra ne mažesnis kaip 1,5 101°.KSV bei sudaro maždaug 40 kompozicijos masės %, o likusią dalį sudaro papildomos medžiagos, susidedančios iš maltodekstrinas, maždaug 35,19 kompozicijos masės %, magnio stearatas maždaug 1,17 kompozicijos masės %, silicio dioksidas sudaro maždaug 0,29 kompozicijos masės % bei želatininė kapsulė maždaug 2,2 kompozicijos masės %.The exemplary capsule has a dry biomass of at least 1.5 10 1 ° .KSV and has a total bioactivity of about 40% by weight of the composition, the remainder being maltodextrin supplemental material, about 35.19% by weight of the composition, magnesium stearate at ca. 1.17% by weight of the composition, silica contains about 0.29% by weight of the composition, and the gelatin capsule contains about 2.2% by weight of the composition.
Claims (6)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| LT2013502A LT6202B (en) | 2013-08-02 | 2013-08-02 | Composition for nutritional or pharmaceutical biopreparation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| LT2013502A LT6202B (en) | 2013-08-02 | 2013-08-02 | Composition for nutritional or pharmaceutical biopreparation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| LT2013502A LT2013502A (en) | 2015-02-25 |
| LT6202B true LT6202B (en) | 2015-07-27 |
Family
ID=52478118
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LT2013502A LT6202B (en) | 2013-08-02 | 2013-08-02 | Composition for nutritional or pharmaceutical biopreparation |
Country Status (1)
| Country | Link |
|---|---|
| LT (1) | LT6202B (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2003136785A (en) | 2003-12-22 | 2005-08-10 | Закрытое акционерное общество "БИОКАД" (RU) | THERAPEUTIC AND PREVENTIVE BIOLOGICAL PRODUCT BASED ON DRY BIOMASS BIFIDO- AND LACTOBACTERIA, BIOLOGICALLY ACTIVE ADDITIVE ON FOOD ON THE BASIS OF DRY BIOMASS BIBIDOFIT AND LIEF |
| RU2261909C1 (en) | 2004-10-20 | 2005-10-10 | Общество с ограниченной ответственностью "Мир биотехнологий (НПО)" | BIFIDUS-BACTERIUM CONSORTIUM OF Bifidobacterium bifidum, Bifidobacterium longum, Bifidobacterium adolescentis, Bifidobacterium infantis, Bifidobacterium breve USEFUL IN PREPARATION OF FERMENTED-MILK AND NONFERMENTED PRODUCTS, BIOACTIVE SUPPLEMENT, BIFIDOBACTERIA- CONTAINING PRODUCT, COSMETIC AND TOILETRY AGENTS |
| LT5578B (en) | 2007-08-20 | 2009-06-25 | Uab "Bifidum Medical" | The composition of nutritional or pharmaceutical biopreparation |
-
2013
- 2013-08-02 LT LT2013502A patent/LT6202B/en not_active IP Right Cessation
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2003136785A (en) | 2003-12-22 | 2005-08-10 | Закрытое акционерное общество "БИОКАД" (RU) | THERAPEUTIC AND PREVENTIVE BIOLOGICAL PRODUCT BASED ON DRY BIOMASS BIFIDO- AND LACTOBACTERIA, BIOLOGICALLY ACTIVE ADDITIVE ON FOOD ON THE BASIS OF DRY BIOMASS BIBIDOFIT AND LIEF |
| RU2261909C1 (en) | 2004-10-20 | 2005-10-10 | Общество с ограниченной ответственностью "Мир биотехнологий (НПО)" | BIFIDUS-BACTERIUM CONSORTIUM OF Bifidobacterium bifidum, Bifidobacterium longum, Bifidobacterium adolescentis, Bifidobacterium infantis, Bifidobacterium breve USEFUL IN PREPARATION OF FERMENTED-MILK AND NONFERMENTED PRODUCTS, BIOACTIVE SUPPLEMENT, BIFIDOBACTERIA- CONTAINING PRODUCT, COSMETIC AND TOILETRY AGENTS |
| LT5578B (en) | 2007-08-20 | 2009-06-25 | Uab "Bifidum Medical" | The composition of nutritional or pharmaceutical biopreparation |
Also Published As
| Publication number | Publication date |
|---|---|
| LT2013502A (en) | 2015-02-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102624867B1 (en) | Bifidobacterium breve 207-1 and uses thereof | |
| US20180207165A1 (en) | Methods and compositions for stimulating beneficial bacteria in the gastrointestinal tract | |
| WO2022041656A1 (en) | Lactobacillus paracasei 207-27 and application thereof | |
| US20120020942A1 (en) | Novel Lactobacillus Strains And Their Use Against Helicobacter Pylori | |
| US20100166721A1 (en) | Probotic compositions and uses thereof | |
| US20110165127A1 (en) | Dairy-derived probiotic compositions and uses thereof | |
| US20140147427A1 (en) | Spray-Dried Lactobacillus Stems/Cells and the Use of Same Against Helicobacter Pylori | |
| CN116570631A (en) | Uses of Microbiomes for Human and Animal Health | |
| CN101626774A (en) | Composition for improving intestinal microflora | |
| TW200902040A (en) | Probiotics in a pre-and/or post-surgical environment | |
| JP2008529535A (en) | Food containing probiotics and isolated β-glucan and methods of use thereof | |
| WO2012023578A1 (en) | Agent for improvement in survival of lactic acid bacterium and/or bifidobacterium | |
| GB2418431A (en) | Metabolically active micro organisms and methods for their production | |
| FR2989002A1 (en) | COMPOSITIONS BASED ON PROBIOTICS AND A BEEPOLLEN / CLAY COMPLEX, THEIR PREPARATION AND THEIR USES IN NUTRITION AND THERAPEUTICS | |
| US20220192246A1 (en) | Composition and method for synbiotics supplement containing probiotics, digestive enzymes, prebiotics, yeast, protein, b vitamins, and flavoring agent | |
| CN113950325A (en) | Tributyrin compositions and methods | |
| Lokhande et al. | A systematic study of probiotics-an update review | |
| Panesar et al. | Probiotics, prebiotics and synbiotics: opportunities, health benefits and industrial challenges | |
| JP5238166B2 (en) | Interleukin 12 production inhibitor | |
| Vijaya Kumar et al. | Beneficial effects of probiotics and prebiotics on human health | |
| CN119110844A (en) | Microencapsulated microbial culture preparations with high storage stability | |
| KR100868777B1 (en) | Food composition with Bifidobacterium adolescentis to utilize RS-3 type resistant starch | |
| Sip et al. | Probiotics and prebiotics | |
| LT6202B (en) | Composition for nutritional or pharmaceutical biopreparation | |
| Ozdal | Overview of Probiotics from a Biotechnological Perspective |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| BB1A | Patent application published |
Effective date: 20150225 |
|
| FG9A | Patent granted |
Effective date: 20150727 |
|
| MM9A | Lapsed patents |
Effective date: 20180802 |